MORPHINE SPREADS COLON CANCER

Blocking signal molecule can prevent growth of large intestine and colon cancer

September 23rd, 2009 in Medicine & Health / Cancer http://www.physorg.com/print172915513.html

By seeing what substances and molecules affect the development of our diseases, we can develop drugs that prevent or cure diseases. In her dissertation at Kalmar University in Sweden, Ann Novotny has found that the signal molecule acetylcholine (ACh) is important for the progress of cancer of the large intestine and colon, knowledge that is important to factor in when developing drugs that block the effects of Ach on tumor cells.

Cancer of the large intestine and colon is the third most common cancer form in the Western world. Survival over a five-year period in Sweden is roughly 56 percent, but depends on how far the cancer has spread when it is discovered. It is known that the cancer has developed ways to signal in order to be able grow and spread independently of the regulatory systems of normal cells. In order to increase the number of survivors, it is important to map this signaling so that new forms of treatment for the cancer can be devised.
 
Ann Novotny studied the signaling used by the cancer in a portion of large intestinal and colon cancer. She found that there are receptors for opioids, such as morphone, on tumor cells. If morphine is supplied to these cells the protein urokinase is released, which the cancer cells can use to enhance their capacity to spread.
 
She also studied the nerve signaling molecule acetylcholine (ACh) and discovered that the cancer cells both build up and degrade the molecule. The study shows that the molecule is constantly released from the tumor cells and binds to a special receptor on the same cells, which leads to increased cell production as well as increased production of urokinase, which enhances the ability of the cancer cells to spread. These receptors can also be activated by nicotine, but also by the peptide SLURP-1 (secreted mammalian Ly-6/urokinase plasminagen activator receptor-related protein-1).
 
The levels of several enzymes, receptors, and the peptide SLURP-1 differ in early and late cancer of the large intestine and in healthy and diseased colons. This knowledge should help us develop drugs that block the effects of acetylcholine on tumor cells, which should be able to keep this cancer from developing further.

Provided by The Swedish Research Council

http://www.physorg.com/print172915513.htmlhttp://www.physorg.com/print172915513.html

Comments

[fso]

By the time morphine starts being administered, the end is near.

This study could be very significant in that it would affect trials of anti-cancer drugs on late stage patients. Discarded therapies many have to be re-evaluated as will existing therapies in the presence of non-opiates.
7 posted on Wednesday, September 23, 2009 9:44:39 AM by fso301

[rockingham]

This result further supports the use of low dose naltrexone as an opiate receptor antagonist in cancer treatment.

http://www.lowdosenaltrexone.org/ldn_and_cancer.htm
24 posted on Wednesday, September 23, 2009 10:38:58 AM by Rockingham

[wayne lusvardi]

From Wikipedia on Urokinase

The most important inhibitors of urokinase are the serpins plasminogen activator inhibitor-1 (PAI-1) and plasminogen activator inhibitor-2 (PAI-2), which inhibits the protease activity irreversibly.

Urokinase and Cancer

Elevated expression levels of urokinase and several other components of the plasminogen activation system are found to be correlated with tumor malignancy. It is believed that the tissue degradation following plasminogen activation, facilitates tissue invasion and thus contributes to metastasis. This makes urokinase an attractive drug target and inhibitors have been sought to be used as anticancer agents. However incompatibilities between the human and murine system hampers clinical evaluation of these agents. Through its interaction with the urokinase receptor, urokinase affects several other aspects of cancer biology such as cells adhesion, migration and cellular mitotic pathways.